IMPORTANCE Antidepressants are one of the most commonly prescribed classes of psychotropic medications among US youths. For adults, there is emerging evidence on the increased risk of type 2 diabetes in association with antidepressant use. However, little is known about the antidepressant treatment-emergent risk of type 2 diabetes among youths.
A ntidepressants are one of the most commonly prescribed psychotropic medication classes among US youths.
1,2 In the past 2 decades, there has been a marked increase in the percentage of US children and adolescents who use antidepressants (from 1.5% in 1996-1998 to 2.6% in [2010] [2011] [2012] . 1 This expansion of antidepressant use among youths was driven largely by a significantly more rapid increase in antidepressants prescribed to youths by pediatricians and other primary care physicians than by psychiatrists. 3 For youths, several antidepressants have evidence-based indications approved by the US Food and Drug Administration, such as major depressive disorder, obsessive-compulsive disorder, and childhood enuresis, 4 but their off-label use among youths is also not uncommon, which is a subject of concern and debate. 5, 6 During the past decade, there has been a growing number of published studies-all conducted for adults-that report a substantially increased risk of type 2 diabetes associated with antidepressant use.
7-14 By contrast, evidence of such a risk among youths is scarce and limited to only a few studies, 15, 16 wherein antidepressant use concomitant with antipsychotics was associated with an additive increased risk of type 2 diabetes. To our knowledge, no population-based study has comprehensively examined the independent effect of antidepressants on the risk of incident type 2 diabetes among youths. We conducted a large, retrospective cohort study of youths insured by Medicaid who initiated treatment with antidepressants, and we assessed the risk of incident type 2 diabetes by antidepressant subclass and according to duration of use and cumulative dose. Subsequently, in a secondary analysis, we assessed the risk of type 2 diabetes according to the average daily dose and examined the interaction between the duration of use and the average daily dose for selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), the leading antidepressant subclass. 17 
Methods

Data Source
The Medicaid Analytic eXtract (MAX) database was obtained to analyze computerized administrative claim files from 4 large, geographically diverse states-California, Florida, Illinois, and New Jersey-from January 1, 2004, through December 31, 2009 . 18 Medicaid administrative claims data include enrollment files and claim files for inpatient and outpatient services and prescription drug dispensings. The enrollment files contain data on monthly enrollment, eligibility status, and sociodemographic characteristics. An encrypted identification number was assigned to each enrollee to link enrollment files to inpatient, outpatient, and prescription drug claim files. The inpatient and outpatient claim files contain information at the claim level, including diagnosis and procedure codes. The prescription drug claim file includes information on dispensing date, days of supply, quantity of supply, and national drug code, which was used to identify the name, strength, dosage form, and formulation of dispensed products. This study was reviewed and approved by the University of Maryland institutional review board. As this is a retrospective study with no patient contact and deidentified patient information, no patient consent was needed.
Study Design and Population
In this retrospective cohort study, the study population comprised youths insured by Medicaid who were 5 to 20 years of age. To attenuate prevalent user bias, 19 ,20 a new-user design was applied by restricting the study cohort to those who initiated treatment with antidepressant medications (SSRIs or SNRIs, tricyclic or other cyclic antidepressants [TCAs] , and other antidepressants) from January 1, 2005, through December 31, 2009 (eTable 1 in the Supplement). The flowchart in Figure 1 illustrates the inclusion and exclusion criteria that were applied to define the study cohort of 119 608 youths who initiated antidepressant treatment. The antidepressant initiation date served as the index date for cohort entry. New users of antidepressants were selected by excluding youths who received antidepressant medications during the 365 days preceding the index date. In addition, we excluded youths who were partially enrolled during the 365 days preceding the index date. Youths were also excluded if they had an enrollment in a comprehensive or behavioral managed care plan in Florida because of concerns about the quality of managed care data from Florida. To ensure that there would be an active contact with the health care system, youths were required to have at least 2 outpatient visits (on separate days) in the 365 days prior to the index date. Other criteria (an admission to a long-term care facility or hospice care and a diagnosis of a life-threatening or serious somatic condition [eTable 2 in the Supplement]) were applied to exclude youths who might have received frequent care in noncommunity settings. Because gestational diabetes is common during pregnancy and oral antidiabetic medications (eg, metformin) are frequently used to treat women with polycystic ovarian syndrome, 21 these cases were excluded. Finally, because the main objective of the study was to assess incident type 2 diabetes, youths were excluded if they had a diabetes-related inpatient or outpatient claim or an antidiabetic medication dispensed during the 365-day period prior to the index date.
Incident Type 2 Diabetes
The main study outcome was diagnosis of incident type 2 diabetes, which was identified by the use of a validated, comput-
Key Points
Question Does antidepressant use increase the risk of incident type 2 diabetes among youths?
Findings In a cohort study of youths insured by Medicaid that included 119 608 youths who initiated antidepressant treatment, the current use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors-the most commonly used antidepressant subclass-was associated with an increased risk of incident type 2 diabetes that intensified with increasing duration of use, cumulative dose, and average daily dose.
Meaning
The study findings provide an impetus to improve monitoring for benefits vs risks of antidepressant use in pediatric care models and to shed light on the underlying biological mechanism of antidepressant treatment-emergent type 2 diabetes. encounter. Youths were excluded from meeting the case definition if they had a polycystic ovarian syndrome-related medical encounter within 120 days of the diagnosis date of diabetes. Cases were considered type 1 diabetes if insulin was the sole treatment within 120 days of the diagnosis date of diabetes. Otherwise, the cases were considered type 2 diabetes. The incidence of type 2 diabetes was expressed as the number of new cases of type 2 diabetes per 10 000 person-months of follow-up. Youths in the study were followed up until the incident type 2 diabetes, their 21st birthday, the end of continuous enrollment in the state Medicaid programs, or the end of the study (December 31, 2009), whichever came first. During follow-up, youths were also censored if they had a diabetesrelated medical care encounter that did not meet the case definition of type 2 diabetes (ie, type 1 diabetes, having a dispensing of an antidiabetic medication in the absence of a diabetes diagnosis, or having a polycystic ovarian syndrome-related medical encounter within 120 days of the diagnosis date of diabetes).
Antidepressant Medication Use
In this cohort of youths who initiated antidepressant treatment, medication use was operationalized using 4 time-dependent measures, which accounted for status of use (current vs former use), duration of use (in days), cumulative dose exposure, and average daily dose. Medication use was considered current if medications were not discontinued for more than 90 days. The rationale for the 90-day time period was to account for carryover effects 23 and to allow a reasonable time window for the latency or detection of antidepressant treatment-emergent type 2 diabetes. Medication use was considered former if medications were discontinued for more than 90 days. Of note, we also conducted a sensitivity analysis in which we did not require the 90-day time window to account for the carryover effects. The duration of use was calculated in each month of follow-up as the sum of the total days of supply that were available starting from the cohort entry date (index date). Although the 90-day time period was applied to account for carryover effects in categorizing months of current use, the duration-of-use measure was calculated solely using the days of supply information. Similarly, the cumulative dose was calculated as the sum of total dosage that was available starting from the index date. To set comparable doses across antidepressant medications, the cumulative dosage was calculated in fluoxetine dosage equivalents (in milligrams) (eTable 3i nt h eSupplement). The dose conversion factors were adapted from previously published clinical research. 24, 25 Finally, the average daily dose (milligrams per day) for current users was calculated (in a time-dependent manner) as the cumulative dose (in fluoxetine equivalents) divided by the duration of use.
Statistical Analysis
All analyses were conducted using SAS, version 9.3 (SAS Institute Inc). Discrete-time failure models were used to assess the adjusted incidence of type 2 diabetes. The unit of analysis in these models was person-months. Discrete-time analyses provide computational efficiency and practical advantages over Cox proportional hazards regression models when there are multiple time-dependent medication exposure groups. 26, 27 To adjust for confounding, we identified more than 125 baseline and time-dependent covariates that encompassed a wide range of sociodemographic, administrative, and regional char- The duration-response and dose-response analyses were not conducted for TCAs owing to low frequency of use. For current users of SSRIs or SNRIs, we assessed the risk of type 2 diabetes according to the duration of SSRI or SNRI use and the cumulative SSRI or SNRI dose. Similarly, for current users of other antidepressants, we assessed the risk of type 2 diabetes according to the duration of use and the cumulative dose of other antidepressants.
Furthermore, we conducted secondary analyses to explore whether the average daily dose would be associated with the risk of type 2 diabetes for SSRIs or SNRIs, the leading antidepressant subclass. Also, we assessed whether the risk of type 2 diabetes associated with the average daily dose differs according to the duration of use (ie, the interaction between the average daily dose and the duration of use).
We conducted several subgroup and sensitivity analyses. We conducted an analysis of older youths (10-20 years of age) wherein antidepressant use was most prevalent. 1, 17 In another analysis, we did not require the 90-day time window to account for the carryover effects. Moreover, we excluded youths who used any other psychotropic medication prior to the index date. The latter analysis (in psychotropic medication-naive youth) attempted to attenuate confounding by disease severity because prior use of other classes of psychotropic medications could suggest greater severity of a psychiatric condition. Finally, to attenuate confounding by indication, we conducted an analysis by restricting the cohort to youths with a diagnosis of depressive disorders.
Results
Characteristics of the Study Cohort
The study cohort comprised 119 608 youths aged 5 to 20 years who initiated treatment with antidepressants from 2005 through 2009 (Table 1) . The study cohort largely represented youths who were between 10 and 17 years of age (83 122 [69.5%]), 
Risk of Incident Type 2 Diabetes
During follow-up, there were 233 incident cases of type 2 diabetes, of which 156 occurred during current use (absolute risk, 1.16 per 10 000 person-months) and 77 occurred during former use of antidepressants (absolute risk, 0.56 per 10 000 person-months) ( Table 2) . Overall, when compared with former use, current use of antidepressants was associated with a 1.92-fold increased risk of type 2 diabetes (95% CI, 1.43-fold to 2.57-fold increased risk). The risk of type 2 diabetes according to current vs former use differed by antidepressant medication subclass (in terms of both absolute risk and relative risk [RR] estimates). Compared with former use, current use of SSRIs or SNRIs (absolute risk, 1.29 per 10 000 person-months vs 0.64 per 10 000 person-months; RR, 1.88; 95% CI, 1.34-2.64) or TCAs (absolute risk, 0.89 per 10 000 person-months vs 0.48 per 10 000 person-months; RR, 2.15; 95% CI, 1.06-4.36) was associated with an increased risk of type 2 diabetes. By contrast, current use of other antidepressants was not significantly associated with an increased risk of type 2 diabetes compared with former use (absolute risk, 1.15 per 10 000 person-months vs 1.12 per 10 000 person-months; RR, 0.99; 95% CI, 0.66-1.50).
Furthermore, for youths currently using SSRIs or SNRIs, the risk of type 2 diabetes intensified with increasing duration of SSRI or SNRI use, with an RR of 2.66 (95% CI, 1.45-4.88) for more than 210 days of use and an RR of 2.56 (95% CI, 1.29-5.08) for 151 to 210 days of use compared with 1 to 90 days of use ( Table 3) . By contrast, for current users of other antidepressants, the duration of use was not significantly associated with an increased risk of type 2 diabetes. Similar significant findings were observed when the risk of type 2 diabetes was assessed according to the cumulative dose. For youths currently using SSRIs or SNRIs, the risk of type 2 diabetes intensified with increasing cumulative dose (in fluoxetine hydrochloride dose equivalents) ( Table 3) . Compared with youths with a 1-to 1500-mg cumulative SSRI or SNRI dose exposure, there was a 2.44-fold increased risk (95% CI, 1.35-to 4.43-fold increased risk) of type 2 diabetes among youths with more than a 4500-mg SSRI or SNRI cumulative dose and a 2.17-fold increased risk (95% CI, 1.07-to 4.40-fold increased risk) of type 2 diabetes among youths with a 3001-to 4500-mg cumulative SSRI or SNRI dose. By contrast, for youths who were currently using other antidepressants, the cumulative dose was not significantly associated with an increased risk of type 2 diabetes.
Finally, because both the duration and the cumulative dose were associated with an increased risk of type 2 diabetes in youths currently using SSRIs or SNRIs, we explored the interaction between the duration of use and the average daily dose on the risk of type 2 diabetes (Figure 2) . Overall, for youths currently using SSRIs or SNRIs, the risk of type 2 diabetes increased significantly with the average daily dose (in fluoxetine hydrochloride dose equivalents), with an RR of 1.96 (95% CI, 1.05-3.64) for more than 30.0 mg/d and an RR of 1.83 (95% CI, 1.04-3.24) for 15.1 to 30.0 mg/d compared with 15.0 mg/d or less. However, the risk of type 2 diabetes associated with the average daily dose differed according to the duration of SSRI or SNRI 
Sensitivity and Subgroup Analyses
Discussion
In this large cohort of youths insured by Medicaid who initiated treatment with antidepressant medications, our main finding indicates that there was a substantially greater risk of incident type 2 diabetes for those currently using SSRIs or SNRIs than for those who formerly used these medications. Furthermore, for youths currently using SSRIs or SNRIs, the risk of type 2 diabetes intensified with increasing duration of use, cumulative dose, and average daily dose. The increased risk was most apparent for youths with long-term SSRI or SNRI use at higher average daily doses. Current use of TCAs was also associated with an increased risk of type 2 diabetes. By contrast, current use of other antidepressants was not associated with an increased risk of type 2 diabetes. Moreover, for patients currently using other antidepressants, neither duration nor cumulative dose was associated with an increased risk of type 2 diabetes.
There is a dearth of published reports examining the risk of type 2 diabetes associated with pediatric use of antidepressants. To our knowledge, this is the first population-based study of youths that comprehensively examines the risk of incident Abbreviations: SNRIs, serotonin-norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors.
a All regression models were adjusted for disease risk score (expressed as percentile ranks), time from cohort entry (ie, follow-up month), and exposure to tricyclic and other related cyclic antidepressants. In youths currently using SSRIs or SNRIs, the use of other antidepressants was also adjusted. Likewise, in youths currently using other antidepressants, the use of SSRIs or SNRIs was also adjusted.
b The cumulative dose was calculated in fluoxetine hydrochloride equivalents. 
Strengths and Limitations
In this large cohort of youths insured by Medicaid, we used a new-user design to mitigate prevalent user bias, 20 and we used a previously validated algorithm to assess incident type 2 diabetes. 22 Also, we nested our study solely in a cohort of youths who initiated antidepressant treatment wherein the incidence of type 2 diabetes was assessed according to current vs former use (rather than comparing users vs nonusers). This approach aimed to attenuate bias due to unmeasured confounding since current users should be more similar to former users than to nonusers regarding factors associated with antidepressant use. [39] [40] [41] In addition, for current users, we conducted duration-response and dose-response analyses, all of which provided consistent estimates for SSRIs and SNRIs (significantly increased risk) and other antidepressants (no significantly increased risk). Several limitations should also be noted. First, causality cannot be inferred from observational studies; thus, the study findings should be interpreted with caution. Nevertheless, the study used a rigorous design and rigorous statistical approaches to account for confounding, and it provides new information on the risk of a rare, but serious, adverse outcome that is often difficult to assess in randomized clinical trials owing to limited sample size and inadequate follow-up. 42 
Conclusions
In a large cohort of youths insured by Medicaid, the use of SSRIs and SNRIs was associated with an increased risk of type 2 diabetes, which intensified with increasing duration of use, cumulative dose, and average daily dose. The increased risk was particularly prominent for long-term use of SSRIs or SNRIs that occurred in greater daily doses. In the face of recent growth in the pediatric use of antidepressants in the United States, as well as other Western countries, 17,44 the findings from this study support the need for further research to shed light on the underlying biological mechanism of treatmentemergent type 2 diabetes associated with antidepressants. Also, given that more than half of antidepressant prescriptions to US youths occur in outpatient visits to pediatricians and other primary care physicians, 3 the study findings provide an impetus for policy development to improve monitoring for the benefits vs risks of antidepressant use in pediatric care models, specifically for serotonin reuptake inhibitors, the most commonly used antidepressant subclass. Adjusted for disease risk score (expressed as percentile ranks), time from cohort entry (i.e., follow-up month), and exposure to tricyclic and other related cyclic antidepressants b SSRI/SNRI: Selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor
